These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20093814)

  • 1. Aldosterone in uremia - beyond blood pressure.
    Ritz E; Koleganova N
    Blood Purif; 2010; 29(2):111-3. PubMed ID: 20093814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of high salt intake and the response of the cardiovascular system to aldosterone.
    Conlin PR
    Cardiol Rev; 2005; 13(3):118-24. PubMed ID: 15831143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid receptor activation in obesity hypertension.
    Nagase M; Fujita T
    Hypertens Res; 2009 Aug; 32(8):649-57. PubMed ID: 19521418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension.
    Gaddam KK; Pratt-Ubunama MN; Calhoun DA
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):353-9. PubMed ID: 16716096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Involvement of Aldosterone and mineralocorticoid receptor in pathogenesis of cardiovascular diseases].
    Miyamori I
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():144-6. PubMed ID: 15171358
    [No Abstract]   [Full Text] [Related]  

  • 7. Expanding view of aldosterone action, with an emphasis on rapid action.
    Vinson GP; Coghlan JP
    Clin Exp Pharmacol Physiol; 2010 Apr; 37(4):410-6. PubMed ID: 20409082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?
    Bansal S; Lindenfeld J; Schrier RW
    Circ Heart Fail; 2009 Jul; 2(4):370-6. PubMed ID: 19808361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normokalemic hyperaldosteronism in patients with resistant hypertension.
    Benchetrit S; Bernheim J; Podjarny E
    Isr Med Assoc J; 2002 Jan; 4(1):17-20. PubMed ID: 11802302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vascular actions of aldosterone.
    Briet M; Schiffrin EL
    J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spironolactone, amiloride, losartan, and thiazide (SALT) double-blind crossover trial in patients with low-renin hypertension and elevated aldosterone-renin ratio.
    Hood SJ; Taylor KP; Ashby MJ; Brown MJ
    Circulation; 2007 Jul; 116(3):268-75. PubMed ID: 17606839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone and end-organ damage.
    Marney AM; Brown NJ
    Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary hyperaldosteronism in a patient with end-stage renal disease.
    Kazory A; Weiner ID
    Nephrol Dial Transplant; 2007 Mar; 22(3):917-9. PubMed ID: 17127694
    [No Abstract]   [Full Text] [Related]  

  • 15. [Spironolactone: renaissance of anti-aldosterone therapy in heart failure?].
    Brilla CG; Schencking M; Scheer C; Rupp H
    Praxis (Bern 1994); 1997 Apr; 86(14):566-74. PubMed ID: 9198851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension.
    Mahmud A; Feely J
    Am J Hypertens; 2005 Jan; 18(1):50-5. PubMed ID: 15691617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of atrial natriuretic factor on blood pressure and the renin-angiotensin-aldosterone system.
    Atlas SA; Volpe M; Sosa RE; Laragh JH; Camargo MJ; Maack T
    Fed Proc; 1986 Jun; 45(7):2115-21. PubMed ID: 2940120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monogenic hypertension].
    Bähr V; Oelkers W; Diederich S
    Med Klin (Munich); 2003 Apr; 98(4):208-17. PubMed ID: 12715144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aldosterone receptor antagonism in heart failure.
    Jennings DL; Kalus JS; O'Dell KM
    Pharmacotherapy; 2005 Aug; 25(8):1126-33. PubMed ID: 16207104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldosterone, hypertension, and beyond.
    Samavat S; Ahmadpoor P; Samadian F
    Iran J Kidney Dis; 2011 Mar; 5(2):71-6. PubMed ID: 21368382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.